Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Filgotinib in Ulcerative Colitis
2016-002765-58Phase 3Active
- Sponsor
- Gilead Sciences
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of filgotinib in autoimmune colitis, sponsored by Gilead Sciences. Primary endpoint: Safety. Started Dec 2016; status: active.
02
Drugs
filgotinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-002765-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002765-58.